# PANKU-Breast02 (NCT06382142)

> A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

No report yet. It can be ordered.

- Drugs tested: izalontamab brengitecan (BL-B01D1)
- Indication: unresectable locally advanced or metastatic triple-negative breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06382142
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Conditions: Triple-Negative Breast Cancer
- Interventions: BL-B01D1; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
- Enrollment: 418
- Primary outcome: Progression-free survival (PFS)
- Primary outcome: Overall survival (OS)

## Questions raised in the commentary

_Automated from all 16 indexed sources (Feb 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether results will be confirmed in a global population
- Whether iza-bren has a role in earlier treatment settings
- Whether hematologic toxicity is manageable

Also discussed: EGFR-HER3 targeting beyond TROP2.

## Indexed commentary on PANKU-Breast02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=panku-breast02-nct06382142

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06382142", "email": "<work email>"}; the inbox owner confirms by the emailed link.